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Deletion of Cyclophilin D Impairs 
β-Oxidation and Promotes Glucose 
Metabolism
Michele Tavecchio1, Sofia Lisanti1, Michael J. Bennett2, Lucia R. Languino3 & Dario C. Altieri1
Cyclophilin D (CypD) is a mitochondrial matrix protein implicated in cell death, but a potential role in 
bioenergetics is not understood. Here, we show that loss or depletion of CypD in cell lines and mice 
induces defects in mitochondrial bioenergetics due to impaired fatty acid β-oxidation. In turn, CypD 
loss triggers a global compensatory shift towards glycolysis, with transcriptional upregulation of 
effectors of glucose metabolism, increased glucose consumption and higher ATP production.  
In vivo, the glycolytic shift secondary to CypD deletion is associated with expansion of insulin-
producing β-cells, mild hyperinsulinemia, improved glucose tolerance, and resistance to high fat 
diet-induced liver damage and weight gain. Therefore, CypD is a novel regulator of mitochondrial 
bioenergetics, and unexpectedly controls glucose homeostasis, in vivo.
In addition to providing cellular energy1, mitochondria play a key role in the initiation of programmed 
cell death, or apoptosis2. Many of the molecular requirements of this response, including the participa-
tion of Bcl-2 family proteins3, and stepwise loss of organelle integrity4, have been elucidated in detail, as 
well as their impact on disease5. However, other aspects of this process are less well-defined, in particular 
the function of a mitochondrial permeability transition pore (PTP)6, whose increased conductance in 
response to cell death stimuli causes swelling of the matrix, uncoupling of the electron transport chain 
(ETC), and release of apoptogenic proteins, notably cytochrome c7, in the cytosol. In this context, the 
mitochondrial matrix peptidyl-prolyl cis,trans isomerase, Cyclophilin D (CypD) has long been recog-
nized as a constituent of the PTP8, but the involvement of other organelle proteins in pore formation 
has been debated9,10, and the impact of this pathway on necrotic versus apoptotic cell death has remained 
elusive11.
In addition, there is evidence that CypD may have broader role(s) in cellular homeostasis beyond 
PTP function. Largely inferred from the phenotype(s) of CypD deletion or silencing, this may involve 
mitochondria-to-nuclei retrograde signaling in cell proliferation and migration12, regulation of mitochon-
drial DNA transcription and cellular oxygen consumption13,14, modulation of macrophage inflamma-
tory responses15, and metabolic adaptation, in vivo16,17. In particular, how CypD may affect metabolism, 
including glucose homeostasis, has been controversial in the literature, with evidence suggesting that 
CypD deficiency is associated with insulin resistance17 or, conversely, protects against insulin resistance, 
in vivo18. Elucidating a role of CypD in metabolism is significant, as pharmacologic inhibition of CypD 
protects against tissue damage during myocardial19, or cerebral20 ischemia-reperfusion injury, as well as 
neuronal loss21, validating this pathway as a therapeutic target in heart disease22,23, neurodegeneration24 
and possibly metabolic imbalance.
In this study, we explored a role of CypD in metabolism, and its potential impact on glucose home-
ostasis and high fat diet-associated tissue damage.
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Results
CypD regulation of mitochondrial bioenergetics. We began this study by profiling the metabo-
lome of wild type (WT) or CypD knockout (KO) mouse embryonic fibroblasts (MEFs), characterized 
in recent studies12. Deletion of CypD was accompanied by multiple defects in mitochondrial TCA cycle 
intermediates (Fig. 1A). These included reduced acetyl CoA levels, accumulation of malate and fumarate, 
depletion of glutamine with concomitant elevation of α -ketoglutarate, potentially suggestive of compen-
satory glutaminolysis, and decreased levels of the byproduct, succinylcarnitine (Fig.  1B). Despite the 
defects in cellular respiration, individual mitochondrial oxidative phosphorylation Complex I (Fig. 1C), 
Complex II (Fig. 1D), Complex III (Fig. 1E), Complex IV (Fig. 1F) and Complex V (Fig. 1G) had com-
parable activity in WT or CypD KO MEFs.
In addition, deletion of CypD was accompanied by an accumulation of acylcarnitine species, con-
sistent with defective mitochondrial fatty acid β -oxidation (Fig. 2A). One of the key regulators of mito-
chondrial fatty acid metabolism is the α /β octameric trifunctional protein (TFP), which catalyzes the 
Figure 1. CypD deletion affects TCA cycle but not oxidative phosphorylation. (A,B) Wild type (WT) 
or CypD KO MEFs were analyzed in a global metabolomics screen (n = 5), and changes in expression 
of metabolites implicated in TCA cycle are schematically represented (A) and quantified (B). Cellular 
extracts were used and values were normalized on protein content. For box plots in (B), relative metabolite 
abundance is represented. The limit of upper and lower quartiles, median values (straight line), and 
maximum and minimum distribution are shown. Cross, mean value; circle, extreme data point. Only 
significant changes (p < 0.05) are shown. (C–G) Mitochondria or mitochondrial extracts (see Material 
and Methods section) isolated from primary hepatocytes of WT or CypD KO mice (one out of three 
independent experiments is shown) were analyzed for activity of oxidative phosphorylation Complex I 
(C), Complex II (D), Complex III (E), Complex IV (F) and Complex V (G). Tracings (left) correspond to 
individual activity reactions. Bar graphs (right), individual mitochondrial complex activity normalized to 
citrate synthase activity, n = 3.
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four chain-shortening reactions in β -oxidation, including 3-hydroxyacyl-CoA dehydrogenase (HADH)25. 
Accordingly, TFP activity was significantly reduced in liver extracts from CypD KO mice, compared 
to WT littermates (Fig.  2B). In addition, recombinant CypD immunoprecipitated from MEF extracts 
contained endogenous TFP (Fig.  2C), and, reciprocally, FLAG-TFP immune complexes contained 
co-associated CypD (Fig.  2D). In cycloheximide block experiments, deletion of CypD did not signifi-
cantly affect TFP stability and turnover, compared to WT cultures (Fig. 2E). Consistent with impaired 
mitochondrial bioenergetics, CypD loss resulted in decreased content of cofactors, NADH, NAD+ and 
FAD (Fig. 2F). This response was accompanied by increased levels of lactate and glucose, suggestive of 
heightened glucose metabolism, and overall higher ATP production in CypD KO MEFs, compared to 
WT cultures (Fig.  2F). Consistent with metabolic shift, CypD KO hepatocytes exhibited global tran-
scriptional changes in bioenergetics effectors, with increased mRNA expression of genes involved in 
Figure 2. Involvement of CypD in mitochondrial β-oxidation. (A) Heatmap of protein-normalized 
quantification of acylcarnitine levels in WT or CypD KO MEFs in the presence of 5 mM glucose. The figure 
represents the average of three independent experiments, each run in triplicate. The individual acylcarnitines 
are indicated. Bold names indicate statistically significant differences. Darkest blue indicates lowest level, 
darkest red indicates highest level. (B) TFP activity was assessed in WT and CypD KO mitochondrial 
liver extracts. The panel shows a representative experiment out of two, each run in triplicate. (C,D) CypD 
WT MEFs were transfected with a Myc-CypD (C) or FLAG-TFP (D) cDNA, immunoprecipitated with an 
antibody to Myc or FLAG, respectively, and immune complexes were analyzed by Western blotting. The two 
panels are from two different experiments, therefore are from two different electrophoresis runs. No image 
manipulations were performed and images were cropped only to bring close the two proteins that have a 
quite different molecular weight. Full gels images are in Supplementary informations file, Fig. 5. The panels 
show a representative experiment out of two. (E) WT or CypD KO MEFs were treated with cycloheximide 
(CHX), harvested at the indicated time points, and analyzed by Western blotting. The panel shows a 
representative experiment out of two. The right and left panels are from the same experiment, samples were 
loaded on two different gels as many time points were performed and could not be allocated on one gel. 
The development was performed together on the same films. No image manipulations were performed and 
images were cropped only to bring close the two proteins that have a quite different molecular weight and 
to indicate the two gels. Full gels images are in Supplementary informations file, Fig. 6. (F) Wild type (WT) 
or CypD KO MEFs were analyzed in a global metabolomics screen (n = 5). Cellular extracts were used and 
values were normalized on protein content. Relative metabolite abundance is represented. The limit of upper 
and lower quartiles, median values (straight line), and maximum and minimum distribution are shown. 
Cross, mean value; circle, extreme data point. Only significant changes (p < 0.05) are shown.
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glucose metabolism (Pdk), gluconeogenesis (Fbp1, Pck1) and glycolysis (AldoB, Eno2, Galm, Gapdh, 
HK3, Pgam2) (Supplementary Figure 1A–C). In contrast, TCA gene products were largely unchanged 
between WT and CypD KO MEFs (Supplementary Figure 1D).
CypD deletion induces enhanced glycolysis. Consistent with defective mitochondrial β -oxidation, 
CypD KO hepatocytes exhibited significantly reduced oxygen consumption, compared to WT cultures 
(Fig. 3A). To establish a role of CypD in this response, we next carried out reconstitution experiments 
in CypD KO MEF. In these experiments, reconstitution of CypD KO cells with CypD cDNA (Fig. 3B) 
restored O2 consumption indistinguishably from WT cells, whereas a control plasmid was ineffective 
(Fig.  3C). To independently validate our findings, we next silenced the expression of Hadha, one of 
the two subunits of the TFP, and looked at potential changes in cellular respiration. In these exper-
iments, siRNA silencing of Hadha in WT MEF significantly inhibited oxygen consumption to levels 
Figure 3. Glucose metabolism switch secondary to CypD deficiency. (A) Primary hepatocytes isolated 
from WT or CypD KO mice were analyzed for oxygen consumption at the indicated cell densities. The panel 
shows a representative experiment out of two, each run in triplicates. RFU = Relative Fluorescence Unit. 
(B,C) CypD KO MEFs were reconstituted with vector or a CypD cDNA and analyzed by Western blotting 
(B) and changes in O2 consumption at increasing time intervals (C) RFU = Relative Fluorescence Unit. 
WT MEFs were analyzed as control. The panel shows a representative experiment out of two, each run in 
triplicates. The two panels in (B) are from the same experiment, therefore are from the same electrophoresis 
run. No image manipulations were performed and images were cropped only to bring close the two proteins 
that have a quite different molecular weight. Full gels images are in Supplementary informations file, Fig. 
7. (D,E) MEFs (D) or primary hepatocytes (E) isolated from WT or CypD KO mice were analyzed for 
lactate production. The panel shows a representative experiment out of two, each run in triplicates. (F) WT 
or CypD KO MEFs were analyzed for pyruvate production. The panel shows a representative experiment 
out of two, each run in triplicates. (G) MEFs were analyzed for glucose consumption. The panel shows a 
representative experiment out of two, each run in triplicates. (H,I) CypD KO MEFs were reconstituted with 
vector or increasing concentrations of a CypD cDNA (0.1, 0.25, 0.5 and 1 μ g/ml) and analyzed for glucose 
consumption (H) or lactate production (I). Mean ± SD of a representative experiment. (J–L) Primary 
hepatocytes (J) or MEFs (K) isolated from WT or CypD KO mice were analyzed for ATP production. The 
panel shows a representative experiment out of two, each run in triplicates. (L) Glioblastoma LN229 cells 
stably transfected with control shRNA or CypD-directed shRNA were analyzed for ATP production. The 
panel shows a representative experiment out of two, each run in triplicates.
www.nature.com/scientificreports/
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observed in CypD KO cells (Supplementary Figure 4A). Together with the results above (Fig.  1C–G), 
these data support the model that CypD deletion impairs cellular respiration by decreasing β -oxidation, 
without directly affecting oxidative phosphorylation. To confirm the sensitivity of the approach, we next 
quantified oxygen consumption in lung adenocarcinoma A549 ρ o cells, which have been depleted of 
mitochondrial DNA and are thus respiration-incompetent. Compared to parental A549 cells, which had 
robust oxygen consumption, A549 ρ o cells were ineffective (Supplementary Figure 4B), thus validating 
the experimental protocol used. In agreement with the data of metabolomics profiling, CypD deletion in 
MEFs or primary hepatocytes was associated with increased production of lactate (Fig. 3D,E), as well as 
pyruvate (Fig. 3F). This was associated with heightened glucose consumption (Fig. 3G). We next exam-
ined the specificity of these responses, and reconstitution of CypD KO cells with CypD cDNA normal-
ized glucose consumption (Fig. 3H), as well as lactate production (Fig. 3I), compared to control plasmid. 
Together, the increased glucose metabolism associated with CypD deletion resulted in higher levels of 
ATP production in hepatocytes (Fig.  3J) or MEFs (Fig.  3K). In addition, stable shRNA knockdown of 
CypD in glioblastoma LN229 cells also resulted in increased ATP production, compared to control cul-
tures transfected with non-targeting shRNA (Fig. 3L).
CypD deletion heightens glucose metabolism, in vivo. Next, we looked at the implications of 
glucose metabolism in KO versus WT CypD mice, in vivo. In glucose tolerance tests, both male and 
female CypD KO mice exhibited faster normalization of glycemia, compared to WT CypD littermates 
(Fig.  4A,B and supplementary Figure 2A,B). Similar results were obtained in pyruvate tolerance tests, 
with more rapid normalization of glycemia in CypD KO mice, compared to WT animals after systemic 
administration of pyruvate (Fig. 4C and supplementary Figure 2C). Under these conditions, livers from 
Figure 4. In vivo glucose metabolism is enhanced in CypD KO mice. (A,B) WT or CypD KO male 
(A) or female (B) mice were challenged in a glucose tolerance test with i.p. injection of glucose (2 mg/g), 
and analyzed for blood glucose levels at the indicated time intervals The panel shows a representative 
experiment out of two, each run in triplicates (C) WT or CypD KO mice were challenged with i.p. injection 
of pyruvate (2 mg/g) and analyzed for blood glucose levels at the indicated time intervals. The panel shows a 
representative experiment out of two, each run in triplicates. (D) WT or CypD KO mice were injected with 
glucose and analyzed for changes in liver glycogen after 30 min. Three animals per group, each measured 
three times. (E) Pancreas tissues were isolated from 3-mo old WT or CypD KO mice and weighed. 
n = 5. (F,G) Pancreas sections from WT or CypD KO mice were stained with an antibody to insulin by 
immunohistochemistry (F), and labeled areas were quantified and multiplied by relative intensity (G). 
Magnification, x20; data represent 14 different fields out of 5 WT animals, compared to 19 fields out of 5 
KO animals. (H) Blood samples collected from WT or CypD KO mice were analyzed for insulin levels. Each 
point corresponds to an individual animal. n = 17, each measured in triplicate.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:15981 | DOi: 10.1038/srep15981
CypD KO mice exhibited reduced glycogen content following a bolus of glucose, as compared with CypD 
WT animals (Fig.  4D). A potential mechanism for the improved glucose tolerance observed in CypD 
KO mice was next investigated. Accordingly, pancreas tissues collected from CypD KO mice exhibited 
increased weight, (Fig. 4E), and higher number of insulin-producing islet β -cells, compared to WT ani-
mals (Fig. 4F,G). Consistent with these data, CypD KO mice showed higher levels of circulating plasma 
insulin than WT littermates (Fig. 4H).
The potential implications of glucose metabolism in CypD KO mice were further investigated. 
Exposure of WT mice to a 12-week course of high-fat diet (HFD) resulted in glucose intolerance in 
response to systemic administration of a glucose bolus, while KO animals were protected and cleared 
glucose even faster than their LFD-fed counterpart (Fig. 5A and supplementary Figure 2D). In addition, 
CypD WT mice exposed to HFD exhibited hyperinsulinemia, while KO mice were protected (Fig. 5C). 
Moreover, WT animals exposed to HFD exhibited progressive weight gain (Fig. 5B,D), and increase in 
liver weight (Fig.  5E). Histologically, this was associated with extensive tissue damage and lipid accu-
mulation (Fig. 5F). In contrast, CypD KO mice treated with HFD under the same conditions normal-
ized blood glucose levels within 90 minutes of bolus injection (Fig.  5A), and showed no weight gain 
(Fig. 5B,D). By the end of treatment, HFD-fed CypD KO mice showed no changes in liver weight com-
pared to control animals fed normal diet (Fig. 5E), and had no histologic evidence of lipid accumulation 
in the liver (Fig.  5F and Supplementary Figure 3). Other organs, including heart, spleen and kidneys 
showed no weight difference in WT or CypD KO mice fed low- or high-fat diet (Fig.  5E). In analysis 
of liver extracts, WT mice exposed to HFD revealed increased phosphorylation of kinases associated 
with insulin signaling, including AMPK and its downstream target, ACC, mTOR, and Akt, compared to 
Figure 5. In vivo protective effects induced by CypD deletion. (A,B) WT or CypD KO mice were 
maintained on low-fat diet (LFD) or high-fat diet (HFD) for 12 weeks, and animals in the various groups 
were analyzed for glucose tolerance after i.p. injection of glucose (2 mg/g) (A) or changes in overall 
body weight (compared to LFD animals at day 0, (B). The panels show one out of two representative 
experiments, each run with four animals per group. (C-E) The experimental conditions are as in (A) and 
mice in the various groups were quantified for insulinemia (C), overall body weight (D) or weight of the 
indicated organs (E). (F) Liver sections from representative mice in the various groups as in (B) were 
analyzed histologically by hematoxylin/eosin staining. Magnification, x20. Livers from all the animals were 
analyzed and a representative one from each group is shown. (G) Total liver extracts from WT or CypD 
KO mice exposed to LFD or HFD were analyzed by Western blotting. Three different mice were used for 
each condition. The panel is an entire experiment, therefore from a single electrophoresis run. No image 
manipulations were performed and images were cropped only to bring close the analyzed proteins. Different 
exposures were used for the different proteins, due to their different abudancies and the different antibodies 
avidity. Full gels images are in Supplementary informations file, Fig. 8.
www.nature.com/scientificreports/
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control animals fed normal diet (Fig. 5G). In contrast, CypD deletion was associated with constitutively 
higher levels of phosphorylated kinases, quantitatively similar in high- or low-fat diet (Fig. 5G).
Discussion
In this study, we have identified a novel role of the mitochondrial matrix protein, CypD8 in glucose 
metabolism, insulin production and liver protection in response to high-fat diet, in vivo. Mechanistically, 
this pathway functions as a compensatory response to impaired mitochondrial β -oxidation resulting from 
CypD deletion or depletion, and involves transcriptional upregulation of glucose regulatory molecules, 
improved glucose tolerance, expansion of insulin-producing β -cells and mild hyperinsulinemia, in vivo.
Although long established as a component of the PTP8, and implicated in the execution of cell death11, 
the function(s) of CypD in mitochondrial bioenergetics have remained elusive. Here, a global metab-
olomics screen uncovered broad defects in mitochondrial TCA and β -oxidation and reduced oxygen 
consumption in CypD KO MEFs. Different from previous reports, where CypD deletion did not affect 
cellular respiration14, or reduced the levels of oxidative phosphorylation complex subunits8, we observed 
no difference in the activity of individual mitochondrial oxidative phosphorylation complexes in WT or 
CypD KO liver mitochondria.
Instead, CypD deletion impaired fatty acid oxidation, with accumulation of acylcarnitines, in agree-
ment with previous findings14. Mechanistically, a role of CypD in fatty acid metabolism involves a novel 
association described here between CypD and TFP25, a key effector of organelle β -oxidation26, whose 
activity was significantly reduced in CypD knockout cells. Although more work is required to elucidate 
how an interaction with CypD may affect TFP activity, this pathway does not appear to involve changes 
in TFP stability and/or folding in mitochondria.
Defective mitochondrial fatty acid metabolism in CypD knockout cells was accompanied by tran-
scriptional upregulation of glycolysis mediators and a general switch towards glucose metabolism, with 
higher glucose consumption, lactate levels, and ATP production, all adaptive responses secondary to 
CypD deletion. In turn, the compensatory glucose metabolism associated with CypD deletion resulted in 
improved glucose tolerance, expansion of insulin-producing islet β cells, and sustained hyperinsulinemia, 
in vivo. The impact of CypD on glucose tolerance, in vivo, has been debated. Consistent with the data 
presented here, metabolic profiling studies of CypD-targeted cells also suggested a switch towards gly-
colytic metabolism16. However, the implications of this response in vivo varied greatly, from improved 
glucose tolerance due to better mitochondrial Ca2+ retention capacity, without changes in insulin signa-
ling18, to defective insulin signaling, partially corrected by administration of metformin17. Here, analysis 
of liver tissues from CypD KO mice revealed constitutive upregulation of kinase cascades associated with 
insulin signaling, including phosphorylated Akt, mTOR and AMPK, in a reaction not further modulated 
by exposure to high-fat diet, in vivo.
In this context, metabolic reprogramming and improved glucose tolerance in CypD knockout mice 
protected against liver damage induced by high-fat diet. In keeping with its role as a regulator of necrotic 
cell death11, deletion of CypD has been previously associated with improved tissue protection in response 
to ischemia/reperfusion injury19, and neurodegenerative insults20. In the case of high-fat diet, deletion of 
CypD has also been mechanistically linked to inhibition of cell death, independently of inflammation27, 
as well as prevention of mouse obesity28.
In summary, we have described a novel role of CypD in metabolic switching and glucose bioener-
getics, in vivo. The ability of CypD to control glucose homeostasis and insulin production in vivo (this 
work) should be considered in therapeutic strategies aimed at targeting CypD for neurodegeneration24, 
ischemia-reperfusion injury22,23 and possibly hyperglycemia. Indeed, patients with defective fatty acid 
oxidation due to a mutation in the TFP are maintained on a strict glucose-rich diet29 and TFP KO mice 
exhibit severe hypoglycemia30, thus resembling and strengthening our data and confirming CypD as a 
player in β -oxidation.
The possibility to therapeutically exploit this shift could be used in pathologies where hyperglycemia 
is an important feature, for example diabetes. Consistent with this hypothesis, trimetazidine, an Hadha 
inhibitor used for the treatment of angina pectoris, increases glucose uptake in rat brain31 and has been 
reported to have beneficial effects in diabetic patients32.
Materials and Methods
Cell lines. Wild type (WT) or CypD KO mouse embryonic fibroblasts (MEF) were described pre-
viously12. Glioblastoma LN229 and A549 lung carcinoma cells were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA), and maintained in culture at 37 °C in a 5% CO2 atmosphere 
as recommended by the supplier. Cell types were grown in DMEM plus antibiotics, 10% FBS, glutamine 
and different concentrations of glucose.
Antibodies and reagents. The following antibodies to Trifunctional Protein (TFP) (AbCam, 
ab54477), CypD (Millipore, AP1035), FLAG, β -actin and α -tubulin (Sigma-Aldrich, A8592, A5541, 
T9026) were used. All other antibodies were from Cell Signaling Technology (code for pmTOR: 2971, 
mTOR: 2983, pAMPK: 2535, AMPK: 2603, pACC: 3661, ACC: 3676, pAkt: 9271, Akt: 9272, pGSK3α /β : 
8566).
www.nature.com/scientificreports/
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Metabolomics screen. A global metabolomics screen to examine changes in expression of 301 indi-
vidual metabolites was carried out by Metabolon, Inc. in WT or CypD KO MEFs, as described previ-
ously33. Statistically significant changes were used to build a metabolite set enrichment overview using 
MSEA (Metabolite Set Enrichment Analysis) software.
β-oxidation measurements. Acylcarnitines measurement in WT or CypD KO MEFs was carried 
out by flow-injection tandem mass spectrometry adapted from the method of Shen et al.34. Fifty micro-
liters of cell lysates were placed in a 96 well plate containing stable isotope-labeled internal standards at 
a final concentration of 0.2 μ M (Cambridge Isotope Laboratories, Andover, MA). The lysate was dried 
under a steady stream of nitrogen, followed by the addition of 50 μ L butanolic HCl, sealed and heated 
for 15 min at 65 °C to form butyl-esters. Samples were then dried down under a steady stream of nitro-
gen and finally reconstituted in acetonitrile: water (80:20). Five μ l of this product were directly injected 
into a Xevo-TS S tandem mass spectrometer (Waters Corp. Waltham, MA). Data were acquired in the 
multiple reaction mode where parent compounds of the carnitine-specific fragment of m/z 85 were 
acquired. Acylcarnitines were quantified against the nearest equivalent internal standard by isotope ratio 
measurement. Finally, results were normalized on the protein content.
Immunoprecipitation. Mitochondria from transfected MEF were lysed in 50 mM Tris HCl pH 7.4, 
150 mM NaCl, 1 mM EDTA, 1% Triton X-100 plus protease and phosphatase inhibitors. Five-hundred 
μ g of proteins were pre-cleared with agarose beads, and incubated with a primary antibody to Myc or 
FLAG tags for 16 h at 4 °C. After washes, proteins in precipitated pellets were separated by SDS gel elec-
trophoresis, and western blotting was performed.
Western blotting. Protein lysates were prepared with an extraction buffer containing 150 mM NaCl, 
50 mM Tris pH 8.0, 1% Triton X-100, in the presence of protease and phosphatases inhibitors. Twenty 
μ g of proteins were separated on SDS polyacrylamide gels, blotted onto PVDF membrane and incubated 
with primary antibodies overnight at 4 °C. Incubation with secondary HRP-conjugated antibodies fol-
lowed, and immunoreactive bands were detected with ECL reagents (GE Healthcare, RPN2106).
Hydroxyacyl-CoA dehydrogenase (HADHA) activity. Mitochondrial proteins (200 μ g) isolated 
from WT or CypD KO livers were suspended in buffer containing 50 mM MES, 100 mM KH2PO4, 
100 μ M dithiothreitol, 100 μ M NADH, supplemented with 50 μ M 3-oxoacyl-CoA ester and 0.1% Triton 
X-100, pH 6.1. HADHA activity representative of trifunctional protein (TFP) enzymatic activity was 
followed by monitoring the decrease in absorbance at 340 nm. TFP activity was calculated dividing the 
changes in absorbance over time in the linear range of the readings.
Glucose consumption assay. Glucose concentrations in the media were measured by a standard 
glucometer (OneTouch Ultra2). Values from samples were subtracted from the blank (medium with no 
cells) and then normalized on the respective number of cells.
Lactate production assay. 3 μ l of culture media were collected 48 hours after cells seeding and 
were incubated with 50 μ l of Assay Reaction Master Mix for 30 min at 22 °C (L-Lactate Assay Kit – 
Colorimetric Abcam, cat. no. ab65331). Lactate concentration in the various samples were quantified by 
absorbance at 450 nm and values were normalized on the cell number.
Pyruvate production assay. A kit (700470) from Cayman Chemical was used. Medium from MEF 
culture was collected and deproteinized with an equal volume of 0.5 M of metaphosphoric acid. After 
centrifugation, potassium carbonate was added to the supernatant to neutralize the acid. The supernatant 
is then diluted 1:1 with the provided buffer. 20 μ l of each samples are used and additioned with 50 μ l 
of assay buffer, 50 μ l of FAD and thiamine pyrophosphate, 10 μ l of fluorometric detector and 20 μ l of 
pyruvate oxidase and horseradish peroxidase. Ex/Em wavelenghts are 530-540/585-595 nm. Values are 
then normalized on cell number.
ATP production assay. Different cell types were seeded in white 96-well plates. After 24 or 48 hours, 
working solution from the kit (eEnzyme, cat. No. CA-A115) was added, and luminescence was measured. 
Numbers were then normalized on the cell number.
Oxygen consumption assay. Cells were seeded at different densities in black 96 wells plates with 
transparent bottom and 24 hours later medium was changed with DMEM with no phenol red (Gibco, 
11054-020).
The probe from a kit (Enzo Life Sciences 51045-K100) was added and the cells covered with mineral 
oil to avoid flux of oxygen with the atmosphere. At different time points, increase in fluorescence was 
measured at 650 nm, indicating a proportional utilization of oxygen. Numbers were then normalized on 
the number of cells.
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Cytrate Synthase activity assay. Two μ g of mitochondrial preparation were used to evaluate the 
citrate synthase activity, with a Cytrate Synthase kit (ScienCell, cat#8318). The assay is based on the 
reaction between 5′, 5′-Dithiobis-nitrobenzoic acid and CoA-SH to form TNB, which exhibits maximum 
absorbance at 412 nm. The intensity of the absorbance is proportional to the citrate synthase activity.
Mitochondrial complexes activity assays. Complexes I to IV activities were measured using Abcam 
kits number 109721, 109908, 109905 and 109911, respectively, according to manufacturer’s instructions. 
Briefly, mitochondria were lysed (not for complex III measurements) in the provided buffers to obtain 
a 5 μ g/μ L protein solution.
For complex I, 50 μ g of proteins were loaded in every well of the provided plate for immunocapturing. 
After washings, the oxidation of NADH (provided by the kit) to NAD+ was indirectly followed with the 
simultaneous reduction of a provided dye. This reduction was directly proportional to an increase in the 
450 nm absorbance, which was constantly monitored.
For complex II, 300 μ g of proteins were loaded in every well of the provided plate for immunocap-
turing. After washings, Ubiquinone 2 and Succinate were added and Ubiquinol was produced. This was 
coupled with the reduction of the provided dye, monitored by a decrease in absorbance at 600 nm.
For complex III, 12 μ g of intact mitochondria were loaded in every well of the provided plate. After 
washings, Cytochrome C was added and its reduction was followed by the increase in absorbance at 
550 nm. Rotenone was included in the reaction to inhibit complex I, while KCN was used to avoid the 
re-oxydation of Cytochrome C by complex IV.
For complex IV, 100 μ g of proteins were loaded in every well of the provided plate for immunocap-
turing. After washings, Cytochrome C was added and its oxidation was followed by the decrease in 
absorbance at 550 nm.
Complex V activity was evaluated with a kit from Cayman Chemicals (701000). Briefly, freshly iso-
lated mitochondria at 5 μ g/μ L underwent two freeze-thaw cycles and in the final reaction 1 μ g was used 
in each well of a 96 wells plate. The assay is based on the conversion of ATP to ADP by the complex, 
the ADP is then used by pyruvate kinase to form pyruvate from phosphoenolpyruvate. Pyruvate, in the 
presence of lactate dehydrogenase is reduced to lactate and the concomitant reaction oxidizes NADH to 
NAD+. The rate of NADH oxidation was monitored at 340 nm for 30 minutes every 30 seconds at 25 °C.
Complexes activities were calculated dividing the changes in absorbance over time in the linear range 
of the readings. Finally, the results were normalized on Cytrate Synthase activity.
Mitochondrial fractionation. Mitochondria were obtained by use of a commercial kit for isola-
tion (Thermo Scientific, 89874), following the manufacturer’s instructions. Briefly, harvested cells were 
dounce-homogenized and centrifuged at 700 g for 10 minutes. Supernatant were then centrifuged at 
3000 g for 15 minutes, to obtain mitochondria in the pellet. Samples were then snap-frozen in N2 liquid 
and stored at − 80 °C until use.
Hepatocytes isolation. Hepatocytes from 6–8 weeks old mice were isolated with the two-step colla-
genase perfusion method and cultivated in collagen-coated plates for the experiments. Hepatocytes were 
seeded at 200000/mL and kept up to 48 hours in M199 media with 10% FBS and 1% Pen/Strep.
Transfections. Cells were seeded at 2 × 104/ml and 24 hours later transfected with 0.1 μ g/mL of con-
trol or HADHA-Flag or CypD-Myc plasmid DNA using Lipofectamine.
Mice. Pure C57/Bl6 CypD KO mice were kindly donated by Dr. Mike A Forte (Vollum Institute, 
Oregon Health & Sciences University, Portland, Oregon) and were crossed with WT C57/Bl6 (Jackson 
Lab) to obtain heterozygous animal, that were then used to propagate the colony. All animal procedures 
were approved by the Institutional Animal Care and Use Committee (IACUC) at The Wistar Institute 
and experiments were performed in accordance with the relevant guidelines and regulations published 
in the Wistar Institute Guide for Animal Research.
Glucose and pyruvate tolerance test. 8 weeks old mice were food-withdrawn for 16 hours (water 
was provided ad libitum) and then injected intra peritoneum with 2 mg/g of glucose or pyruvate. Glycemia 
was checked at different time points by a standard glucometer (OneTouch Ultra2). Harvested tissues 
were immediately snap-frozen in liquid nitrogen and kept at − 80 °C until processing.
Glycogen measurement. Frozen livers were ground and after lysis of red blood cells a commercial 
kit (Cayman Chemical, cat. #700480) was used, according to manufacturer’s instructions. Briefly, 300 mg 
of ground tissue was homogenized in assay buffer and diluted ten times. 10 μ L were put in every well 
of a 96 wells plates, and then 50 μ L of hydrolysis buffer with amyloglucosidase were added, to convert 
glycogen to β -D-glucose. Glucose oxidase was then added to convert β -D-glucose to hydrogen per-
oxide. Horseradish peroxidase was added and H2O2, in the presence of it, reacted with 10-acetyl-3,7-
dihydroxyphenoxazine to produce resorufin, whose fluorescence was measured at Ex/Em of 540/595 nm.
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Insulin measurements. Insulin was measured with an ELISA kit (Millipore EZRMI-13K), according 
to manufacturer’s protocol, using 10 μ l of mouse serum. Briefly, serum from animals was added to a 96 
wells plate coated with anti-insulin antibody. After extensive washings a biotynilated anti-insulin anti-
body was added and subsequently a streptavidin-conjugated horseradish peroxidase was added. After 
further washings, HRP substrate is added and the increased absorbance at 450 nm is monitored.
Insulin IHC. FFPE pancreas sections were deparaffinised and antigen retrieval was performed by 
heat. After blocking, 1/64000 of anti-insulin antibody (Abcam, ab8304) was added for 16 hours at 4 °C. 
Secondary, HRP-conjugated antibody was added and the reaction was stopped after 2 minutes. After the 
slides were mounted, pictures were taken and the intensity and area of insulin islets were quantified by 
ImageJ and multiplied by each other.
Cholesterol measurements. A kit from Cayman Chemical (10007640) was used. Serum from mice 
under LFD or HFD regimens was collected and diluted 400 times. Briefly, 50 μ L of samples were used and 
additioned with the same volume of assay cocktail, composed by assay buffer, cholesterol detector, HRP 
cholesterol oxidase and cholesterol esterase. Samples were excited at 540 nm and fluorescence detected 
at 595 nm.
Triglycerides measurements. A kit from Cayman Chemical (10010303) was used. Triglycerides 
were measured in serum and feces of mice under LFD or HFD regimens. Briefly, 10 μ L of each sample 
were put in each well, then 150 μ L of enzyme buffer were added and the absorbance was read at 540 nm.
Statistical analysis. Data were analyzed using the two-sided unpaired t-tests using GraphPad soft-
ware. Welch’s correction was applied when the two groups had different sample sizes. Data are expressed 
as mean ± SD from a representative experiment out of three (unless otherwise stated). Replicates num-
bers are indicated in the figure legends. A p value of < 0.05 was considered statistically significant. 
*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
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